Abstract
Brentuximab vedotin (SGN-35) is an antibody–drug conjugate with a high selectivity against CD30+ cell lines and more than 300-fold less activity against antigen-negative cells. In the last years, the results of many in vitro and in vivo studies have led to the fast approval of this drug to treat lymphoma patients. Another innovative method to treat tumor cells including lymphoma cells is the use cytokine-induced killer (CIK) cells, which have also been approved and proven to be a safe treatment with only minor adverse events. In this study, a possible additive effect when combining SGN-35 with CIK cells was investigated. The combinational treatment showed that it reduces the viability of CD30+ cell lines significantly in vitro. Additionally, the amount of lymphoma cells was significantly reduced when exposed to CIK cells as well as when exposed to SGN-35. A significant negative effect of SGN-35 on the function of CIK cells could be excluded. These results lead to the assumption that SGN-35 and CIK cells in combination might achieve better results in an in vitro setting compared to the single use of SGN-35 and CIK cells. Further investigations in in vivo models must be conducted to obtain a better understanding of the exact mechanisms of both treatments when applied in combination.
Highlights
Tumor cells of Hodgkin’s disease (HD) and anaplastic large cell lymphomas (ALCLs) express the tumor necrosis factor receptor (TNFR) family member CD30, making it a diagnostic marker for those lymphomas
LymphDoamudai acnedll KliIn-JeKs, 1a:n10d, t1h:5e, 1C:2IKancdel1ls:1wraetrioesiwnceurebachteodsenfo, rw2h4ileh, f(oFrigLu-5r4e0,11).:1,F2o:r1,t5h:e1saenedx1p0e:1r.iments, Lymphoma cell lines and the cytokine-induced killer (CIK) cells were incubated for 24 h (Figure 1)
The results show that SGN-35 has no significant effect on the cytotoxicity of CIK cells towards the different lymphoma cell lines, except for Daudi (Figure 3)
Summary
Tumor cells of Hodgkin’s disease (HD) and anaplastic large cell lymphomas (ALCLs) express the tumor necrosis factor receptor (TNFR) family member CD30, making it a diagnostic marker for those lymphomas. The safety and the high response rates of SGN-35 as a single agent in clinical trials for relapsed/refractory HL and ALCL, which have been demonstrated in recent studies, led to the quick approval by the Food and Drug Administration to treat lymphoma patients [8]. Since it has been widely used for CD30+ lymphoma therapy and has been shown that it can be reused in clinical applications [9]. Sscpi.e2c01i6fi, c17n, 1a05tu ral killer-like T cells, which are called cytokine-induced killer (2CofIK9 ) cells
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
